Loading patent…
AssigneeHawking Biological Technology Co., Ltd
InventorsShinn-Zong LIN, Horng-Jyh Harn, Tzyy-Wen Chiou, Kuo-Wei Hsueh, Mao-Hsuan Huang
Estimating the term…
A method for providing an increased expression of at least one of telomerase, brain-derived neurotrophic factor (BDNF), stromal cell-derived factor-1 (SDF1), CXC chemokine receptor 4 (CXCR4), and an immune regulatory factor of a stem cell in a subject is provided. The method comprises simultaneously or separately administering to the subject an effective amount of (a) a phthalide and (b) a stem cell.
A method for providing an increased expression of at least one of telomerase, brain-derived neurotrophic factor (BDNF), stromal cell-derived factor-1 (SDF1), CXC chemokine receptor 4 (CXCR4), and an immune regulatory factor of a stem cell in a subject, comprising simultaneously or separately administering to the subject an effective amount of (a) a phthalide and (b) a stem cell, wherein said increased expression is increased in comparison with a corresponding expression of the effective amount of the stem cell in a subject without being administered with a phthalide.
A kit, comprising:
A method for treating a motor neuron degenerative disease and/or delaying the onset of a motor neuron degenerative disease in a subject, comprising administering to the subject an effective amount of a metabolic precursor of a phthalide, wherein the metabolic precursor of a phthalide is 3-butylidene-4,5-dihydrophthalide (ligustilide).
Dependencies are inferred from the claim text.